BioLine Launches New JetSeq DNA Library Preparation Kit

CINCINNATI--(BUSINESS WIRE)--Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the JetSeq™ DNA Library Preparation Kit, the first product in a new line of kits from Bioline for Next Generation Sequencing (NGS) sample preparation.

Developed in collaboration with Oxford Gene Technology (OGT), the JetSeq DNA Library Preparation Kit uses the highly optimized enzymes and buffers to enable the preparation of the highest quality NGS sequencing-ready, adapter-ligated DNA for Illumina’s Next-Generation Sequencers. A combination of end repair and A-tailing followed by direct ligation of the adaptors (supplied in the kit), reduces the hands-on time, making the process faster and easier to use. This also reduces the number of clean-up steps, significantly improving the yield and quality of sequence-ready libraries and reducing the amount of DNA required.

Marco Calzavara, President of Bioline commented, “The release of the JetSeq DNA Library Preparation Kit represents a significant landmark for Bioline, since it is our first product in the NGS space. Our extensive knowledge in the creation of highly efficient enzymes and buffer formulation will mean that researchers will be able to tackle even the most challenging samples with confidence in this very fast moving field.”

Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are excited about the release of the JetSeq DNA Library Preparation Kit and the enhanced performance that it provides for all of our life science customers, from academic and government labs, to pharmaceutical and biotechnology companies, forensics, clinical labs and hospitals, service providers and diagnostics companies. We remain committed to the continued development and expansion of the rapidly growing portfolio of innovative products from Bioline.”

ABOUT MERIDIAN BIOSCIENCE, INC.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

ADDITIONAL INFORMATION

For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com